| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | 575.68% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/11/2023 | 170.27% | JMP Securities | → $4 | Reiterates | Market Outperform → Market Outperform |
| 05/09/2023 | 575.68% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/05/2023 | 170.27% | JMP Securities | → $4 | Maintains | Market Outperform |
| 04/27/2023 | 170.27% | JMP Securities | → $4 | Reiterates | → Market Outperform |
| 03/08/2023 | 170.27% | JMP Securities | → $4 | Reiterates | → Market Outperform |
| 03/03/2023 | 170.27% | JMP Securities | → $4 | Reiterates | → Market Outperform |
| 03/03/2023 | 575.68% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 12/21/2021 | 237.84% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 12/21/2021 | 575.68% | HC Wainwright & Co. | $14 → $10 | Maintains | Buy |
| 08/05/2020 | 35.14% | Morgan Stanley | $4 → $2 | Maintains | Equal-Weight |
| 08/05/2020 | 845.95% | HC Wainwright & Co. | $25 → $14 | Maintains | Buy |
| 04/06/2020 | 575.68% | Citigroup | $14 → $10 | Maintains | Buy |
| 03/18/2020 | 170.27% | Morgan Stanley | $11 → $4 | Maintains | Equal-Weight |
| 03/17/2020 | 305.41% | Stifel | $18 → $6 | Downgrades | Buy → Hold |
| 01/09/2020 | 1116.22% | Stifel | $10 → $18 | Upgrades | Hold → Buy |
| 12/16/2019 | 845.95% | Citigroup | → $14 | Initiates Coverage On | → Buy |
| 06/17/2019 | 845.95% | Goldman Sachs | → $14 | Initiates Coverage On | → Buy |
| 12/20/2018 | 575.68% | Morgan Stanley | $26 → $10 | Maintains | Equal-Weight |
| 12/20/2018 | 440.54% | Barclays | $30 → $8 | Downgrades | Overweight → Equal-Weight |
| 12/20/2018 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/20/2018 | 1251.35% | JMP Securities | $30 → $20 | Reiterates | → Market Outperform |
| 11/02/2018 | 1927.03% | B of A Securities | $33 → $30 | Maintains | Buy |
| 09/14/2018 | 2264.86% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 09/11/2018 | 1724.32% | Morgan Stanley | $28 → $27 | Maintains | Equal-Weight |
What is the target price for DBV Technologies (DBVT)?
The latest price target for DBV Technologies (NASDAQ: DBVT) was reported by HC Wainwright & Co. on August 1, 2023. The analyst firm set a price target for $10.00 expecting DBVT to rise to within 12 months (a possible 575.68% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for DBV Technologies (DBVT)?
The latest analyst rating for DBV Technologies (NASDAQ: DBVT) was provided by HC Wainwright & Co., and DBV Technologies reiterated their buy rating.
When is the next analyst rating going to be posted or updated for DBV Technologies (DBVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DBV Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DBV Technologies was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
Is the Analyst Rating DBV Technologies (DBVT) correct?
While ratings are subjective and will change, the latest DBV Technologies (DBVT) rating was a reiterated with a price target of $0.00 to $10.00. The current price DBV Technologies (DBVT) is trading at is $1.48, which is within the analyst's predicted range.